Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of RSVΔG live-attenuated RSV vaccine in healthy adults
NL-OMON19920Phase 1Active, not recruiting
- Sponsor
- Intravacc
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of RSVΔG live-attenuated respiratory syncytial virus vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Intravacc. Primary endpoints: Naso-oropharyngeal pain during and shortly after administration, Treatment-emergent adverse events and serious adverse events and 2 more. Started May 2018; status: active, not recruiting.
02
Drugs
RSVΔG live-attenuated respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON19920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19920.